MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Richardson, Paul G.
Hofmeister, Craig C.
Siegel, David
Lonial, Sagar
Laubach, Jacob P.
Efebera, Yvonne A.
Vesole, David H.
Nooka, Ajay K.
Rosenblatt, Jacalyn
Raje, Noopur
Zaki, Mohamed H.
Hua, Ye
Li, Yan
Shah, Sheetal
Wang, Jianming
Anderson, Kenneth C.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1969
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in the MM-003 trial.
    Weisel, Katja
    Moreau, Philippe
    Gibson, Craig J.
    Song, Kevin W.
    Saunders, Owain
    Sternas, Lars Axel
    Hong, Kevin
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Zheng, Cheng
    Dubin, Franck
    van de Velde, Helgi
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S424
  • [43] Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
    Trudel, Suzanne
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Quach, Hang
    Vorobyev, Vladimir I.
    Cavo, Michele
    Suzuki, Kazuhito
    Robak, Pawel
    Morris, Kristin
    Phillips-Jones, Amy
    Zhou, Xiaoou Linnette
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Mateos, Maria-Victoria
    Dimopoulos, Meletios Athanasios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA105 - LBA105
  • [44] A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma
    Rosenzweig, Michael
    Sanchez, James
    Chowdhury, Arnab
    Nathwani, Nitya
    Janakiram, Murali
    Htut, Myo
    Sahebi, Firoozeh
    Walker, Tricia
    Pichiorri, Flavia
    Palmer, Joycelynne
    Krishnan, Amrita
    Keats, Jonathan
    Rosen, Steven
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S153 - S153
  • [45] A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Khouri, Jack
    Faiman, Beth
    Wei, Wei
    Grabowski, Dale
    Samaras, Christy Joy
    Mahfouz, Reda
    Lazarus, Hillard
    Dean, Robert
    Malek, Eshan
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Rosko, Nathaniel
    Fada, Sherry
    Kalaycio, Matt
    Liu, Hien
    Saunthararajah, Yogen
    Chew, Yap
    Valent, Jason
    Reu, Frederic
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E262 - E263
  • [46] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    van de Velde, Helgi
    Anderson, Kenneth C.
    LANCET ONCOLOGY, 2022, 23 (03): : 416 - 427
  • [47] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
    Attal, Michel
    Richardson, Paul G.
    Rajkumar, S. Vincent
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Corzo, Kathryn P.
    Campana, Frank
    Le-Guennec, Solenn
    Dubin, Franck
    Anderson, Kenneth C.
    LANCET, 2019, 394 (10214): : 2096 - 2107
  • [48] Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)
    Cavo, Michele
    Corradini, Paolo
    Di Raimondo, Francesco
    Petrini, Mario
    Cafro, Anna Maria
    di Toritto, Tommaso Caravita
    Offidani, Massimo
    Semenzato, Gianpietro
    Zambello, Renato
    Lazzaro, Antonio
    Petrucci, Maria Teresa
    Rodeghiero, Francesco
    Simcock, Mathew
    Slaughter, Ana
    Herring, Jennifer
    Peluso, Teresa
    Palumbo, Antonio
    BLOOD, 2015, 126 (23)
  • [49] An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Corradini, Paolo
    Cavo, Michele
    Delforge, Michel
    Weisel, Katja C.
    Ocio, Enrique M.
    Di Raimondo, Francesco
    Hansson, Markus
    Simcock, Mathew
    Miller, Neil
    Slaughter, Ana
    Peluso, Teresa
    Sternas, Lars
    Zaki, Mohamed H.
    Moreau, Philippe
    BLOOD, 2015, 126 (23)
  • [50] MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI)
    Matous, Jeffrey
    Siegel, David Samuel DiCapua
    Duong, Hien Kim
    Kasserra, Claudia
    Sternas, Lars
    Jacques, Christian
    Klesczewski, Kenneth
    Zaki, Mohamed H.
    Shah, Jatin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345